⌘K
t
Tissue Regenix Group plc announced that David Cocke retired from his role as Chief Financial Officer today, 01 August 2025. Brandon Largent, Associate Vice President of Finance at Tissue Regenix, was appointed to replace David in a non-board role as Interim CFO with immediate effect.
| Date | 1 Aug 2025 |
| Time | 07:00:10 |
| Category | Board changes |
| ID | 4475T |
Tissue Regenix Group plc
('Tissue Regenix' or 'the Group')
Directorate Change
Appointment of Interim CFO
Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that following initial notification at the final results for the year ended 31 December 2024, David Cocke will retire today from his role as Chief Financial Officer ('CFO'). Brandon Largent, Associate Vice President of Finance at Tissue Regenix will replace David in a non-board role as Interim CFO with immediate effect.
Brandon has over 25 years' experience leading financial operations across PE-backed, private and publicly listed companies. Prior to his role as Associate Vice President of Finance at Tissue Regenix, Brandon was Financial Planning & Analysis Manager (Commercial Division) for Groundworks, a provider of patented groundwork solutions, leading a post-acquisition finance transformation and post-merger integration for Groundworks' entry into the commercial sector. Brandon has also held positions as CFO of Merlin One Aircraft, an US$8M private charter aviation firm and as Finance Manager (US Operations) at Tissue Regenix from 2020-2022.
Daniel Lee, CEO of Tissue Regenix, commented: "We are pleased to appoint Brandon Largent as interim CFO. The Group will undergo a seamless transition as we benefit from Brandon's working knowledge of Tissue Regenix and his previous experiences in financial leadership roles."
"I would like to congratulate David on a well-earned retirement. David's contributions and accomplishments have been instrumental in the Company's growth and success over the past several years. David will be a missed presence among the Tissue Regenix team, but we wish him much happiness and every success in his next chapter."
For more information:
|
Tissue Regenix Group plc |
|
|
Daniel Lee, Chief Executive Officer David Cocke, Chief Financial Officer |
via Walbrook PR |
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Broker) |
|
|
Geoff Nash/Giles Balleny/Edward Whiley |
Tel: +44 (0) 20 7466 5000 |
|
Nigel Birks - Life Science Specialist Sales |
|
|
Harriet Ward - ECM |
|
|
|
|
|
Walbrook PR (Financial PR and IR) |
Tel: +44 (0)20 7933 8780 |
|
Alice Woodings |
TissueRegenix@walbrookpr.com |
|
|
|
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries and wound care.